Back to Search Start Over

Deciphering the quality of SARS‐CoV‐2 specific T‐cell response associated with disease severity, immune memory and heterologous response

Authors :
Alberto Pérez‐Gómez
Carmen Gasca‐Capote
Joana Vitallé
Francisco J. Ostos
Ana Serna‐Gallego
María Trujillo‐Rodríguez
Esperanza Muñoz‐Muela
Teresa Giráldez‐Pérez
Julia Praena‐Segovia
María D. Navarro‐Amuedo
María Paniagua‐García
Manuel García‐Gutiérrez
Manuela Aguilar‐Guisado
Inmaculada Rivas‐Jeremías
María Reyes Jiménez‐León
Sara Bachiller
Alberto Fernández‐Villar
Alexandre Pérez‐González
Alicia Gutiérrez‐Valencia
Mohammed Rafii‐El‐Idrissi Benhnia
Daniela Weiskopf
Alessandro Sette
Luis F. López‐Cortés
Eva Poveda
Ezequiel Ruiz‐Mateos
Virgen del Rocío Hospital COVID‐19 and COHVID‐GS Working Teams
Source :
Clinical and Translational Medicine, Vol 12, Iss 4, Pp n/a-n/a (2022)
Publication Year :
2022
Publisher :
Wiley, 2022.

Abstract

Abstract SARS‐CoV‐2 specific T‐cell response has been associated with disease severity, immune memory and heterologous response to endemic coronaviruses. However, an integrative approach combining a comprehensive analysis of the quality of SARS‐CoV‐2 specific T‐cell response with antibody levels in these three scenarios is needed. In the present study, we found that, in acute infection, while mild disease was associated with high T‐cell polyfunctionality biased to IL‐2 production and inversely correlated with anti‐S IgG levels, combinations only including IFN‐γ with the absence of perforin production predominated in severe disease. Seven months after infection, both non‐hospitalised and previously hospitalised patients presented robust anti‐S IgG levels and SARS‐CoV‐2 specific T‐cell response. In addition, only previously hospitalised patients showed a T‐cell exhaustion profile. Finally, combinations including IL‐2 in response to S protein of endemic coronaviruses were the ones associated with SARS‐CoV‐2 S‐specific T‐cell response in pre‐COVID‐19 healthy donors’ samples. These results could have implications for protective immunity against SARS‐CoV‐2 and recurrent COVID‐19 and may help for the design of new prototypes and boosting vaccine strategies.

Details

Language :
English
ISSN :
20011326
Volume :
12
Issue :
4
Database :
Directory of Open Access Journals
Journal :
Clinical and Translational Medicine
Publication Type :
Academic Journal
Accession number :
edsdoj.151fa4595b4d4cc1bf9eb48405abb07b
Document Type :
article
Full Text :
https://doi.org/10.1002/ctm2.802